Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 501 (7467), 421-5

Synthetic Lethal Metabolic Targeting of Cellular Senescence in Cancer Therapy

Affiliations

Synthetic Lethal Metabolic Targeting of Cellular Senescence in Cancer Therapy

Jan R Dörr et al. Nature.

Abstract

Activated oncogenes and anticancer chemotherapy induce cellular senescence, a terminal growth arrest of viable cells characterized by S-phase entry-blocking histone 3 lysine 9 trimethylation (H3K9me3). Although therapy-induced senescence (TIS) improves long-term outcomes, potentially harmful properties of senescent tumour cells make their quantitative elimination a therapeutic priority. Here we use the Eµ-myc transgenic mouse lymphoma model in which TIS depends on the H3K9 histone methyltransferase Suv39h1 to show the mechanism and therapeutic exploitation of senescence-related metabolic reprogramming in vitro and in vivo. After senescence-inducing chemotherapy, TIS-competent lymphomas but not TIS-incompetent Suv39h1(-) lymphomas show increased glucose utilization and much higher ATP production. We demonstrate that this is linked to massive proteotoxic stress, which is a consequence of the senescence-associated secretory phenotype (SASP) described previously. SASP-producing TIS cells exhibited endoplasmic reticulum stress, an unfolded protein response (UPR), and increased ubiquitination, thereby targeting toxic proteins for autophagy in an acutely energy-consuming fashion. Accordingly, TIS lymphomas, unlike senescence models that lack a strong SASP response, were more sensitive to blocking glucose utilization or autophagy, which led to their selective elimination through caspase-12- and caspase-3-mediated endoplasmic-reticulum-related apoptosis. Consequently, pharmacological targeting of these metabolic demands on TIS induction in vivo prompted tumour regression and improved treatment outcomes further. These findings unveil the hypercatabolic nature of TIS that is therapeutically exploitable by synthetic lethal metabolic targeting.

Similar articles

See all similar articles

Cited by 134 articles

See all "Cited by" articles

References

    1. Science. 2010 Sep 17;329(5998):1492-9 - PubMed
    1. Mol Cell. 2005 Apr 29;18(3):283-93 - PubMed
    1. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
    1. Methods Mol Biol. 2012;874:33-44 - PubMed
    1. BMC Cancer. 2005 May 17;5:47 - PubMed

Publication types

MeSH terms

Associated data

Feedback